Last reviewed · How we verify

NCT05100407

Factors Impacting the Prevalence of MDR Bacteria

Completed Last updated 18 August 2022
What this trial tests

trial in Multi-antibiotic Resistance in 400 participants. Completed in 15 May 2022.

Timeline
1 March 2022
Primary endpoint
1 May 2022
15 May 2022

Quick facts

Lead sponsorKufa University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment400
Start date1 March 2022
Primary completion1 May 2022
Estimated completion15 May 2022
Sites1 location across Iraq

Conditions studied

Sponsor

Kufa University

Who can join

Eligibility, any sex, with Multi-antibiotic Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. To determine the prevalence of multidrug resistance bacteria in patient with different infections 2. To evaluate patients' predictive risk factors of antimicrobial resistance 3. To assess the association between patients' factors and prevalence of MDR bacteria

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multi-antibiotic Resistance

Currently open trials in the same condition.

Other Kufa University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05100407.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing